All In Biotech

Free tool

FAERS Monitor: Evrysdi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213535 or its brand name (Evrysdi, Risdiplam). Reports on generic versions are filed under their own applications.

Reports

4,186

Serious

1,909

46% of reports

Hospitalization

893

Death reported

437

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event356
  • diarrhoea300
  • asthenia230
  • pneumonia225
  • death215
  • pyrexia186
  • fatigue162
  • vomiting149
  • muscular weakness146
  • drug ineffective140
  • rash114
  • headache111
  • covid-19110
  • nausea108
  • off label use98

Reports by year received

View as table
YearReports
20193
2020137
2021594
2022559
2023698
20241,378
2025483
2026334

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,973 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
no adverse eventSignal3569.99.02,855
muscular weaknessSignal1466.55.5671
pneumoniaSignal2253.53.1404
covid-19Signal1103.22.6161
astheniaSignal2303.12.7326
pyrexiaSignal1862.72.3201
diarrhoeaSignal3002.32.1235
vomiting1491.61.433
rash1141.31.18
death2151.31.111
fatigue1621.00.90
headache1110.90.71
nausea1080.70.616
off label use980.60.534
drug ineffective1400.50.560

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.